8.94
price up icon3.00%   0.26
after-market Dopo l'orario di chiusura: 8.92 -0.02 -0.22%
loading
Precedente Chiudi:
$8.68
Aprire:
$8.825
Volume 24 ore:
5.56M
Relative Volume:
2.14
Capitalizzazione di mercato:
$1.68B
Reddito:
-
Utile/perdita netta:
$-294.51M
Rapporto P/E:
-2.5112
EPS:
-3.56
Flusso di cassa netto:
$-244.42M
1 W Prestazione:
-14.20%
1M Prestazione:
-29.61%
6M Prestazione:
-64.89%
1 anno Prestazione:
-74.20%
Intervallo 1D:
Value
$8.73
$9.22
Intervallo di 1 settimana:
Value
$8.41
$10.74
Portata 52W:
Value
$6.36
$47.45

Dyne Therapeutics Inc Stock (DYN) Company Profile

Name
Nome
Dyne Therapeutics Inc
Name
Telefono
(781) 786-8230
Name
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Name
Dipendente
192
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
DYN's Discussions on Twitter

Confronta DYN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
DYN
Dyne Therapeutics Inc
8.94 1.68B 0 -294.51M -244.42M -3.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-11 Ripresa Raymond James Outperform
2025-06-02 Ripresa Oppenheimer Outperform
2025-05-29 Iniziato Evercore ISI Outperform
2025-03-12 Iniziato BMO Capital Markets Outperform
2025-03-07 Iniziato Scotiabank Sector Outperform
2024-12-13 Iniziato Robert W. Baird Outperform
2024-11-26 Iniziato RBC Capital Mkts Outperform
2024-10-24 Downgrade JP Morgan Overweight → Neutral
2024-05-21 Reiterato Chardan Capital Markets Buy
2024-04-30 Iniziato Morgan Stanley Overweight
2024-02-20 Iniziato H.C. Wainwright Buy
2023-02-27 Aggiornamento Raymond James Outperform → Strong Buy
2023-02-15 Iniziato Oppenheimer Outperform
2023-01-26 Iniziato Guggenheim Buy
2022-07-20 Iniziato Chardan Capital Markets Buy
2022-07-12 Iniziato Raymond James Outperform
2020-10-12 Iniziato JP Morgan Overweight
2020-10-12 Iniziato Jefferies Buy
2020-10-12 Iniziato Piper Sandler Overweight
2020-10-12 Iniziato Stifel Buy
Mostra tutto

Dyne Therapeutics Inc Borsa (DYN) Ultime notizie

pulisher
Jun 18, 2025

Dyne Therapeutics (DYN) Receives Continued Buy Rating from Guggenheim | DYN Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Dyne Therapeutics: Emergence As A Superior DM1/DMD Player Warrants Rating Upgrade (DYN) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

Dyne Therapeutics (DYN): Baird Lowers Price Target to $32 | DYN Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - FinancialContent

Jun 18, 2025
pulisher
Jun 18, 2025

Dyne at ‘attractive entry point’ following pullback, says Chardan - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Dyne Therapeutics (DYN) Price Target Reduced by Baird | DYN Stoc - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright reiterates buy rating on Dyne Therapeutics stock - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Dyne adjusts regulatory timeline for DYNE-101 after FDA feedback - The Pharma Letter

Jun 18, 2025
pulisher
Jun 17, 2025

Dyne’s DM1 treatment receives FDA breakthrough designation By Investing.com - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Shares Drop 18% Amid Trial Endpoint Revi - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – DYN - Business Wire

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Stock Price, Quotes and Forecasts - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Boosted by DYNE-101 Program Updates | DY - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Rating and Price Target Maintained by Ch - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Why Is Dyne Therapeutics Stock Trading Lower On Tuesday? - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Alters Primary Endpoint in Key Study | D - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Advances DYNE-101 Program with FDA Pathw - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Transcript : Dyne Therapeutics, Inc.Special Call - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Advances DYNE-101 Program with FDA Pathway Update | DYN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Faces Setback with DYNE-101 Approval Del - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Shares Drop 18% Amid Trial Endpoint Revision | DYN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Shares Drop Amid Clinical Trial Revision | DYN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Alters Primary Endpoint in Key Study | DYN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne stock on revised plan for clinical program (DYN:NASDAQ) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Gains FDA Breakthrough Therapy Designati - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Granted Breakthrough Status for DYNE-101 to Treat Myotonic Dystrophy - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics stock falls after updated plan for accelerated approval in DM1 - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Granted Breakthrough Therapy Designation - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol To FDA Elevating VHOT To Primary Endpoint - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting - The Manila Times

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol Elevating vHOT as Primary Endpoint for U.S. Accelerated Approval of DYNE-101 in Myotonic Dystrophy Type 1 - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Announces FDA Breakthrough Therapy - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

FDA Breakthrough: Dyne's DM1 Drug Shows 20% Muscle Strength Gain in Latest Trial Data - Stock Titan

Jun 17, 2025
pulisher
Jun 16, 2025

Dyne Therapeutics to Host Investor Conference Call and - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Dyne Therapeutics To Host Investor Conference Call And Webcast - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET | DYN Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Dyne Therapeutics to Reveal Crucial Data on DYNE-101 DM1 Treatment: Key Clinical Updates Coming Tomorrow - Stock Titan

Jun 16, 2025
pulisher
Jun 12, 2025

Facioscapulohumeral Muscular Dystrophy Pipeline 2025: FDA - openPR.com

Jun 12, 2025
pulisher
Jun 12, 2025

Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at Raymond James - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Dyne Therapeutics (DYN) Receives "Outperform" Rating by Raymond James | DYN Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Dyne Therapeutics (DYN): Analyst Sets Positive Outlook with $37 Price Target | DYN Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 06, 2025

Dyne Therapeutics officer sells shares worth $1,949 By Investing.com - Investing.com Canada

Jun 06, 2025
pulisher
Jun 06, 2025

Dyne Therapeutics officer sells shares worth $1,949 - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Jun 06, 2025
pulisher
Jun 06, 2025

Millennium Management LLC Acquires 31,545 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Dyne Therapeutics Elects New Directors at Annual Meeting - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Dyne Therapeutics to Present New Preclinical Data in - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Dyne Therapeutics (DYN) Unveils Promising Preclinical Data on DY - GuruFocus

Jun 05, 2025

Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):